Tally F P, Jacobus N V
J Antimicrob Chemother. 1983 Dec;12 Suppl D:47-51. doi: 10.1093/jac/12.suppl_d.47.
The in vitro susceptibility of 157 anaerobic bacteria to imipenem was compared with that to cefoxitin, latamoxef (moxalactam) and clindamycin. The isolates were cultured from clinical specimens submitted to Tufts Anaerobic Laboratory between January 1981 and March 1983. Two strains of Bacteroides fragilis only, were highly resistant to imipenem. The incidence of cefoxitin resistance in the Bact. fragilis group has increased at Tufts-New England Medical Center. The data indicate that imipenem is the most active beta-lactam drug against anaerobic bacteria, including Bact. fragilis group of organisms. The only difference, since our original studies with thienamycin, is the recognition of two imipenem-resistant strains of Bact. fragilis.
将157株厌氧菌对亚胺培南的体外敏感性与对头孢西丁、拉氧头孢（羟羧氧酰胺菌素）和克林霉素的敏感性进行了比较。这些分离株取自1981年1月至1983年3月提交给塔夫茨厌氧菌实验室的临床标本。仅两株脆弱拟杆菌对亚胺培南高度耐药。在塔夫茨 - 新英格兰医学中心，脆弱拟杆菌组中头孢西丁耐药的发生率有所增加。数据表明，亚胺培南是针对厌氧菌（包括脆弱拟杆菌组微生物）最具活性的β-内酰胺类药物。自我们最初使用硫霉素进行研究以来，唯一的差异是发现了两株对亚胺培南耐药的脆弱拟杆菌菌株。
